Raw Organic Milk Thistle Seed Powder is probably the single best thing you can take for healing, cleansing and detoxifying your liver. Traditionally it has been used as a natural remedy for problems including cirrhosis, jaundice, hepatitis and gallbladder disorders. Silymarin is the main active ingredient in milk thistle which acts as both an anti inflammatory and antioxidant. However, it is preferential to use milk thistle seed rather than a silymarin extract as the whole herb often has a more balanced effect.

Medical research does suggest that milk thistle, combined with traditional treatment, can improve diabetes. Studies have shown a decrease in blood sugar levels and an improvement in cholesterol in people with type 2 diabetes. By lowering LDL (bad) cholesterol levels, milk thistle may support a healthy heart. Researchers also have found that milk thistle improved insulin resistance, a key characteristic of type 2 diabetes. Diabetes is a serious condition. Talk to your doctor before taking any supplements as they may interfere with your medication.

Some possible benefits of our Raw Organic Milk Thistle Seed Powder may include:

● Benefiting the nervous system
● Providing heart benefits by supporting healthy cholesterol levels
● Protecting pancreas against alcohol damage
● Possibly protecting against UVB rays
● Preventing LDL oxidation
● Cleansing & detoxifying the liver
● Having anti-inflammatory properties
● Having hepaprotective qualities
● Protecting against skin cancer
● Improving Adrenal function
● Protecting against atherosclerosis
● Acting as a powerful antioxidant in liver tissues
● Regenerating liver cells
● Cleansing the Gallbladder
● Inhibiting colon, tongue, & prostate, cancer cell proliferation
● Effectively combating alcoholic cirrhosis
● Valuable in postoperative liver repair
● Reducing inflammation
● Synergistically working with vitamin E as a liver free radical scavenger
● May be used safely in chronic liver disease
● Antioxidant properties
● Immunostimulating properties
● Improving insulin resistance

Suggested Use: Mix 1 teaspoons 3 times daily with juice, yogurt or add to your favorite smoothie.

Botanical Name: Silybum marianum

Other Names: Holy Thistle, Lady's Thistle, Marian Thistle, Silymarin, Mediterranean Thistle, blessed milk thistle, Mary Thistle, Saint Mary's Thistle, Mediterranean Milk Thistle, Variegated Thistle, and Scotch Thistle

Origin: Bulgaria - Certified Organic

Z Natural Foods strives to offer the highest quality organically grown, raw, vegan, gluten free, non-GMO products available and exclusively uses low temperature drying techniques to preserve all the vital enzymes and nutrients. Our raw Milk Thistle Seed powder is certified organic and passes our strict quality assurance which includes testing for botanical identity, heavy metals, chemicals and microbiological contaminants. ZNaturalFoods.com offers Organic Milk Thistle Seed powder packaged in airtight stand-up, resealable foil pouches for optimum freshness. Once opened, just push the air out of the pouch before resealing it in order to preserve maximum potency. Keep your Organic Milk Thistle Seed powder in a cool, dark, dry place.

References:

1. Davis-Searles PR, Nakanishi Y, Kim NC, et al. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res. 2005 May 15;65(10):4448-57.

2. Gallardo-Williams MT, Maronpot RR, Wine RN, Brunssen SH, Chapin RE. Inhibition of the enzymatic activity of prostate-specific antigen by boric acid and 3-nitrophenyl boronic acid. Prostate. 2003 Jan 1;54(1):44-9.

3. Cohen P, Graves HC, Peehl DM, et al. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab. 1992 Oct;75(4):1046-53.

4. Cohen P, Peehl DM, Graves HC, Rosenfeld RG. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol. 1994 Sep;142(3):407-15.

5. Wang P, Cong R, Wang J, Zhang L. Determination of the active flavonoids in silymarine. Se Pu. 1998 Nov;16(6):510-2.

6. Zi X, Agarwal R. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc Natl Acad Sci USA. 1999 Jun 22;96(13):7490-5.

7. Lahiri-Chatterjee M, Katiyar SK, Mohan RR, Agarwal R. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res. 1999 Feb 1;59(3):622-32.

8. Katiyar SK, Korman NJ, Mukhtar H, Agarwal R. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst. 1997 Apr 16;89(8):556-66.

9. Singh RP, Agarwal R. Prostate cancer prevention by silibinin. Curr Cancer Drug Targets. 2004 Feb;4(1):1-11.

10. Available at: http://www.nci.nih.gov/cancertopics/pdq/cam/milkthistle/HealthProfessional/page2. Accessed August 24, 2005.

11. Lee DY, Liu Y. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, Isolated from Silybum marianum (milk thistle). J Nat Prod. 2003 Sep;66(9):1171-4.

12. Zi X, Feyes DK, Agarwal R. Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. Clin Cancer Res. 1998 Apr;4(4):1055-64.

13. Tyagi AK, Agarwal C, Chan DC, Agarwal R. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep. 2004 Feb;11(2):493-9.

14. Singh RP, Agarwal R. A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer. Mutat Res. 2004 Nov 2;555(1-2):21-32.

15. Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apopotosis, and inhibition of angiogenesis. Cancer Epidemiol Biomarkers Prev. 2003 Sept;12(9):933-9.

16. Anon. Silybum marianum (milk thistle). Altern Med Rev. 1999 Aug;4(4):272-4.

17. Laekeman G, De Coster S, De Meyer K. St. Mary’s Thistle: an overview. J Pharm Belg. 2003;58(1):28-31.

18. Wingo PA, Landis S, Ries LA. An adjustment to the 1997 estimate for new prostate cancer cases. CA Cancer J Clin. 1997 Jul;47(4):239-42.

19. Available at: http://apps.nccd.cdc.gov/ uscs/GraphV.asp?group=3f&Year=2001&Gender=MAL&Var1=United+States&TableType=INCI. Accessed August 24, 2005.

20. Available at: http://prg.nci.nih.gov/snapshots/Prostate-Snapshot.pdf. Accessed August 24, 2005.

21. Luper S. A review of plants used in the treatment of liver disease: part 1. Altern Med Rev. 1998 Dec;3(6):410-21.

22. Mallikarjuna G, Dhanalakshmi S, Singh RP, Agarwal C, Agarwal R. Silibinin protects against photocarcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and Akt signaling. Cancer Res. 2004 Sep 1;64(17):6349-56.

23. Altorjay I et al. The effect of silibinin on the free radical scavenger mechanisms of human erythrocytes in vitro. Acta Physiol Hung 1992;80:375-80.

24. Bialecka M. The effect of bioflavonoids and lecithin on the course of experimental atherosclerosis in rabbits. Ann Acad Med Stetin 1997;43:41-56.

25. Bindoli A et al. Inhibitory action of silymarin on lipid peroxide formation in rat liver mitochondria and microsomes. Biochem Pharmacol 1977;26:2405-9.

26. Boigk G et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997;26:643-9.

27. Bokemeyer C et al. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumor activity. Br J Cancer 1996;74:2036-41.

28. Chen H et al. Protective effects of silibinin and tetrandrine on the outcome of spontaneously hypertensive rats subjected to acute coronary artery occlusion. Int J Cardiol 1993;41:103-8.

29. Dehmlow C et al. Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. Life Sci 1996;58:1591- 1600.

30. Dehmlow C et al. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996;23:749-54.

31. Di Giulio AM et al. Inhibition of high glucose-induced protein mono-ADP-ribosylation restores neuritogenesis and sodium-pump activity in SY5Y neuroblastoma cells. J Neurosci Res 1999;57:663-9.

32. Feher J et al. Effect of silibinin on the activity and expression of superoxide dismutase in lymphocytes from patients with chronic alcoholic liver disease. Free Rad Res Commun 1987;3:373-7.

33. Feher J et al. Liver cell protection in toxic liver lesions. Acta Physiol Hung 1989;73:285-91.

34. Feher J et al. Liver-protective action of silymarin therapy in chronic alcoholic liver disease. Orv Hetil 1989;130:2723-7.

35. Ferenci P et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989;9:105-13.

36. Fuchs E et al. Effects of silibinin and of a synthetic analogue on isolated rat heptatic stellate cells and myofibroblasts. Drug Res 1997;47:1383-7.

37. Geller LI et al. Treatment of fatty hepatosis in diabetics. Probl Endokrinol (Mosk) 1993;39:20-2.

38. Germani E et al. Progressive and selective changes in neurotrophic factor expression and substance P axonal transport induced by perinatal diabetes: protection action of antioxidant treatment. J Neurosci Res 1999;57:521-8.

39. Gershbein LL. Action of dietary trypsin, pressed coffee oil, silymarin, and iron salt on 1,2-dimethylhydrazine tumorigenesis by gavage. Anticancer Res 1994;14:1113-6.

40. Gorio A et al. Endogenous mono-ADP-ribosylation in retina and peripheral nervous system. Adv Exp Med Biol 1997;419:289-95.

41. Gower JD et al. Prevention by antioxidants of oxidative damage to rabbit kidneys subjected to cold ischemia. Biochem Pharmacol 1989;38:213-15.

42. Kim DH et al. Silymarin and its components are inhibitors of beta-glucuronidase. Biol Pharm Bull 1994;17:443-5.

43. Kreeman V et al. Silymarin inhibits the development of diet-induced hypercholesterolemia in rats. Planta Med 1998;64:138-42.

44. Lahiri-Chatterjee M et al. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res 1999;59:622-32.

45. Locher R et al. Inhibitory action of silibinin on low density lipoprotein oxidation. Drug Res 1998;48:236-9.

46. Manna SK et al. Silymarin suppresses TNF-induced activation of NF-kappaB, c-Jun N-terminal kinase, and apoptosis. J Immunol 1999;163:6800-9.

47. Mira L et al. Scavenging of reactive oxygen species by silibinin dehemisuccinate. Biochem Pharmacol 1994;48:753-9.

48. Mowrey D. Guaranteed Potency Herbs: Next Generation Herbal Medicine. Keats Publishing, 1990.

49. Onat D et al. Effect of alpha-tocopherol and silibinin dihemisuccinate on the proliferation of human skin fibroblasts. Biotechnol Appl Biochem 1999;29:213-15.

50. Pietroangelo A et al. Antioxidant activity of silibinin in vivo during long-term iron overload in rats. Gastroenterology 1995;109:1941-9.

51. Rui YC et al. Effects of silibinin on production of oxygen free radical, lipoperoxide and leukotrienes in brain following ischemia and reperfusion. Chung Kuo 1990;11:418-21.

52. Saliou C et al. Selective inhibition of NF-kappaB activation by the flavonoid hepatoprotector silymarin in HepG2. Evidence for different activating pathways. FEBS Lett 1998;440:8-12.

53. Sanhuenza J et al. Changes in the xanthine dehydrogenase/xanthine oxidase ratio in the rat kidney subjected to ischemia-reperfusion stress: preventive effect of some flavonoids. Res Commun Chem Pathol Pharmacol 1992;78:211-8.

54. Scambia G et al. Antiproliferative effect of silibinin on gynecological malignancies: synergism with cisplatin and doxorubicin. European J Cancer 1996;32A:877-82.

55. Schonfeld J et al. Silibinin, a plant extract with antioxidant and membrane stabilizing properties, protects exocrine pancreas from cyclosporin A toxicity. CMLS Cell Mol Life Sci 1997; 53:917-20.

56. Schriewer H, Rauen HM. The effect of silibinin dihemisuccinate on cholesterol biosynthesis in rat liver homogenates. Arzneimittelforschung 1977;27:1691-4.

57. Skottova N, Krecman V. Silymarin as a potential hypocholesterolemic drug. Physiol Res 1998;47:1-7.

58. Skottova N, Krecman V. Dietary silymarin improves removal of low density lipoproteins by the perfused rat liver. Acta Univ Palacki Fac Med 1998;141:39-40.

59. Skottova N et al. Activities of silymarin and its flavolignans upon low density lipoprotein oxidizability in vitro. Phytother Res 1999; 13:535-7.

60. Sonnenbichler J et al. Biochemical effects of the flavonolignan silibinin on RNA, protein, and DNA synthesis in rat livers. Progress Clin Biol Res 1986;213:319-31.

61. Sonnenbichler J et al. Stimulatory effects of silibinin and silichristin from the milk thistle Silybum marianum on kidney cells. J Pharmacol Exp Ther 1999;290:1375-83.

62. Strauber RE, Stindl G. Protective effect of silibinin against ethanol-induced cytotoxicity in HepG2 cells. J Hepatol 1999;30 (Suppl):277.

63. Soto CP et al. Prevention of alloxan-induced diabetes in the rat by silymarin. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998;119:125-9.

64. Tang ZJ. Alterations in insulin receptor in injured rats and the effects of dexamethasone and silibinin. Chung Hua 1991;7:214-7.

65. Valenzuela A et al. Selectivity of silymarin on the increase of glutathione content in different tissues of the rat. Planta Med 1989;55:420-2.

66. Valenzuela A et al. Effect of silibinin dihemisuccinate on the ethanol metabolizing systems of the rat liver. Cell Biochem Funct 1989;7:173-8.

67. Valenzuela A, Garrido A. Biochemical bases of the pharmacological action of the flavonoid silymarin and its structural isomer silibinin. Biol Res 1994;27:105-12.

68. Velussi M et al. Long-term (12 months) treatment with antioxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde in cirrhotic diabetic patients. J Hepatol 1997;26:871-9.

69. Zhao J, Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis 1999;20:2101-8.

70. Zhao J et al. Significant inhibition by the flavonoid antioxidant silymarin against 12_Otetradecanoylphorbol 13-acetate-caused modulation of antioxidant and inflammatory enzymes, and coclooxygenase 2 and interleukin-1 alpha expression in SENCAR mouse epidermis: implications in the prevention of stage I tumor promotion. Mol Carcinog 1999;26:321-33.

71. Zi X et al. Novel cancer chemopreventive effects of silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNF alpha. Biochem Biophys Res Commun 1997;239:334-9.

72. Zi X et al. Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468; induction of G1 arrest through an increase in Cip1/p21concommitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. Clin Cancer Res 1998;4:1055-64.

73. Zi X, Agarwal R. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc Natl Acad Sci USA 1999;96:7490-5.

74. Albrecht, M. et al. 1992. Therapy of toxic liver pathologies with Legalon® . Z Klin Med 47:87–92.Bindoli, A., L. Cavallini, N. Siliprandi. 1977

75. Inhibitory action of silymarin of lipid peroxide formation in the rat liver mitochondria and microsomes. Biochem Pharmacol 26(24):2405–2409

76. Campos, R., A. Garrido, R. Guerra, A. Valenzuela. 1989. Silybin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver. Planta Med 55(5):417–419

77. Foster, S. 1995. Milk Thistle Bibliography and Abstracts . Austin, TX: American Botanical Council

78. Hikino, H., Y. Kiso, H. Wagner, M. Fiebig. 1984. Antihepatotoxic actions of flavonolignans from Silybum marianum fruits. Planta Med 50(3):248–250

79. Kiesewetter, E., I. Leodolter, H. Thaler. 1977. [Results of two double-blind studies on the effect of silymarin in chronic hepatitis] [In German]. Leber Magen Darm 7(5):318–323

80. Krecman, V., N. Skottova, D. Walterova, J. Ulrichova, V. Simanek. 1998. Silymarin inhibits the development of diet-induced hypercholesterolemia in rats. Planta Med 64(2):138–142

81. McGuffin, M., C. Hobbs, R. Upton, A. Goldberg. 1997. American Herbal Product Association's Botanical Safety Handbook. Boca Raton: CRC Press

82. Mourelle, M., P. Muriel, L. Favari, T. Franco. 1989. Prevention of CC14-induced liver cirrhosis by silymarin. Fundam Clin Pharm 3(3):183–191

83. Plomteux, G. et al. 1977. Hepatoprotector action of silymarin in human acute viral hepatitis. Int Res Commun Syst 5

84. Saba, P. et al. 1976. Effetti terapeutica della silimarina nelle epatopatie croniche indotte da psicofarmaci. Gaz Med Ital 135:236–251

85. Schulz, V., R. Hänsel, V.E. Tyler. 1998. Rational Phytotherapy: A Physicians' Guide to Herbal Medicine. New York: Springer

86. Skottova, N. and V. Krecman. 1998. Silymarin as a potential hypocholesterolaemic drug. Physiol Res 47(1):1–7

87. Valenzuela, A., C. Lagos, K. Schmidt, L. Videla. 1985. Silymarin protection against hepatic lipid peroxidation induced by acute ethanol intoxication in the rat. Biochem Pharmacol 34(12):2209–2212

88. Wagner, H. 1981. Natural Products as Medicinal Agents . Stuttgart: Hippokrates

89. Wagner, H. et al. 1984. Plant Drug Analysis . Berlin-Heidelberg; New York; Tokyo: Springer Verlag

90. Wang, M. et al. 1996. Hepatoprotective properties of Silybum marianum herbal preparation on ethanol-induced liver damage. Fitoterapia 67(2):166–171